AbbVie Price to Sales Ratio 2010-2023 | ABBV

Historical PS ratio values for AbbVie (ABBV) over the last 10 years. The current P/S ratio for AbbVie as of April 24, 2024 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
AbbVie P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2024-04-24 167.80 5.48
2023-12-31 152.05 $30.64 4.96
2023-09-30 144.81 $31.08 4.66
2023-06-30 129.45 $31.56 4.10
2023-03-31 151.75 $31.94 4.75
2022-12-31 152.40 $32.67 4.66
2022-09-30 125.32 $32.54 3.85
2022-06-30 141.69 $32.27 4.39
2022-03-31 148.65 $31.92 4.66
2021-12-31 122.86 $31.64 3.88
2021-09-30 96.73 $31.54 3.07
2021-06-30 99.90 $30.75 3.25
2021-03-31 94.81 $29.22 3.25
2020-12-31 92.80 $27.69 3.35
2020-09-30 74.83 $25.28 2.96
2020-06-30 82.89 $23.72 3.49
2020-03-31 63.41 $22.95 2.76
2019-12-31 72.72 $22.42 3.24
2019-09-30 61.30 $21.93 2.80
2019-06-30 57.99 $21.65 2.68
2019-03-31 63.42 $21.35 2.97
2018-12-31 71.65 $21.05 3.40
2018-09-30 72.73 $20.50 3.55
2018-06-30 70.54 $19.43 3.63
2018-03-31 71.32 $18.50 3.85
2017-12-31 72.36 $17.61 4.11
2017-09-30 66.02 $16.95 3.90
2017-06-30 53.40 $16.51 3.23
2017-03-31 47.51 $16.12 2.95
2016-12-31 45.19 $15.95 2.83
2016-09-30 45.09 $15.36 2.94
2016-06-30 43.88 $14.79 2.97
2015-12-31 41.12 $13.97 2.94
2015-09-30 37.42 $13.45 2.78
2015-06-30 45.87 $13.54 3.39
2015-03-31 39.63 $13.30 2.98
2014-12-31 43.96 $13.23 3.32
2016-03-31 40.09 $12.68 3.16
2014-09-30 38.51 $12.20 3.16
2014-06-30 37.35 $11.99 3.12
2014-03-31 33.71 $11.84 2.85
2013-12-31 34.35 $11.70 2.94
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $300.196B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86
Innoviva (INVA) United States $0.959B 6.77